Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / PHIO - Phio begins enrollment in phase 1b trial of PH-762 to treat skin cancer

PHIO - Phio begins enrollment in phase 1b trial of PH-762 to treat skin cancer

Phio Pharmaceuticals Corp.
Phio Pharmaceuticals (NASDAQ:PHIO) said it opened patient enrollment in a phase 1b trial of PH-762 to treat advanced melanoma, a type of skin cancer. "We are excited to advance our first-in-human clinical trial for our lead program, PH-762, to treat patients with melanoma. The start of this clinical study marks a significant milestone for Phio and our INTASYL therapeutic platform," said Phio (PHIO) President and CEO Gerrit Dispersyn. The trial, which is being conducted at the Gustave Roussy Institute, will feature a dose escalation of PH-762 monotherapy and and find a suitable dose for phase 2.

For further details see:

Phio begins enrollment in phase 1b trial of PH-762 to treat skin cancer
Stock Information
Company Name: Phio Pharmaceuticals Corp.
Stock Symbol: PHIO
Market: NASDAQ
Website: phiopharma.com
Menu
PHIO PHIO Quote PHIO Short PHIO News PHIO Articles PHIO Message Board
Get PHIO Alerts

News, Short Squeeze, Breakout and More Instantly...